VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Price, Quote, News and Overview
FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR
VX1.DE Quote, Performance and Key Statistics
VERTEX PHARMACEUTICALS INC
FRA:VX1 (2/4/2025, 7:00:00 PM)
459.5
+8.75 (+1.94%)
The current stock price of VX1.DE is 459.5 EUR. In the past month the price increased by 17.4%. In the past year, price increased by 17.7%.
VX1.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.69 | 323.32B | ||
| AMG.DE | AMGEN INC | 14.96 | 149.57B | ||
| 1AMGN.MI | AMGEN INC | 14.81 | 148.09B | ||
| GIS.DE | GILEAD SCIENCES INC | 21.97 | 117.44B | ||
| ARGX.BR | ARGENX SE | N/A | 37.64B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 27.07B | ||
| IDP.DE | BIOGEN INC | 8.75 | 20.15B | ||
| 0QF.DE | MODERNA INC | N/A | 13.30B | ||
| 1MRNA.MI | MODERNA INC | N/A | 13.08B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.95B | ||
| GLPG.AS | GALAPAGOS NV | 6.99 | 1.44B | ||
| NVV1.DE | NOVAVAX INC | N/A | 1.30B |
Related stock screener links
About VX1.DE
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 5,400 full-time employees. The firm is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. The company has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The company is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS US
Employees: 5400
Company Website: https://www.vrtx.com/
Investor Relations: https://investors.vrtx.com/
Phone: 16173416393
VX1.DE FAQ
What is the stock price of VX1.DE?
The current stock price of VX1.DE is 459.5 EUR.
What is the symbol for VERTEX PHARMACEUTICALS INC stock?
The exchange symbol of VERTEX PHARMACEUTICALS INC is VX1 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is VX1.DE stock listed?
VX1.DE stock is listed on the Deutsche Boerse Ag exchange.
Is VX1.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for VX1.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of VX1.DE.
Does VX1.DE stock pay dividends?
VX1.DE does not pay a dividend.
When does VX1.DE stock report earnings?
VX1.DE will report earnings on 2025-02-10, after the market close.
What is the Price/Earnings (PE) ratio of VX1.DE?
The PE ratio for VX1.DE is 937.76. This is based on the reported non-GAAP earnings per share of 0.49 and the current share price of 459.5 EUR.
VX1.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VX1.DE. When comparing the yearly performance of all stocks, VX1.DE turns out to be only a medium performer in the overall market: it outperformed 51.05% of all stocks.
VX1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to VX1.DE. VX1.DE scores excellent on profitability, but there are some minor concerns on its financial health.
VX1.DE Financial Highlights
Over the last trailing twelve months VX1.DE reported a non-GAAP Earnings per Share(EPS) of 0.49. The EPS increased by -96.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.16% | ||
| ROE | -3.07% | ||
| Debt/Equity | 0.01 |
VX1.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to VX1.DE. The Buy consensus is the average rating of analysts ratings from 40 analysts.
For the next year, analysts expect an EPS growth of -96.21% and a revenue growth 10.42% for VX1.DE